Ternium shows strong growth with a 5% rise in Mexican steel shipments and a 50% jump in adjusted EBITDA to $717 million in Q2. The company’s major Pasqueria expansion, aimed at USMCA automotive clients, is delayed to early 2027, posing execution and cash flow risks. Despite challenges from Brazil and Argentina demand, Ternium’s valuation model suggests a 32% upside to $75.67 per ADS, contingent on successful project delivery and resolution of a $599 million litigation risk involving Usiminas.
Ternium stock and its outlook come with notable market context from the Basic Materials sector on Pluang. For readers following this sector, here is Pluang's market snapshot as of Sep 18, 2026 07:01 WIB: out of 31 priced US Basic Materials stocks, 25 rose and 6 fell today. Among movers, ArcelorMittal SA (MT) stands out with a price of USD 75.06 and 100% buy order activity, contrasting with Barrick Gold Corp (B) at USD 43.70 with 87% sell orders, and Vale SA (VALE) at USD 14.51 with a more balanced 55% sell to 45% buy split. Typical hold times vary widely, from 35 days for MT to 108 days for VALE.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
